We believe this hybrid nanoplatform can be a promising drug delivery system for cancer treatment by modifying the transferrin and liposomes with other active compounds, and could easily enable industrial production to meet the criteria for clinical trials due to its simple preparation process. Here, TF is linked to cancer.